Liver function tests are to be performed regularly in patients treated with agomelatine. The medicinal product should be discontinued immediately if an increase in transaminases exceeds 3 times the upper limit of normal or if typical symptoms of potential liver damage are observed. Special caution is necessary in patients with transaminases already elevated prior to treatment with agomelatine or with risk factors for developing hepatic damage.

Download DHPC/Information letter , Download_VeroeffentlichtAm_EN 2012.10.25 PDF, 190KB, File is accessible